Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line
- 1 September 2002
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 9 (18) , 1262-1270
- https://doi.org/10.1038/sj.gt.3301797
Abstract
At the forefront of medicine, Gene Therapy brings you the latest research into genetic and cell-based technologies to treat disease. It also publishes Progress & Prospects reviews and News and Commentary articles, which highlight the cutting edge of the field.Keywords
This publication has 27 references indexed in Scilit:
- A binary adenoviral vector system for expressing high levels of the proapoptotic gene baxGene Therapy, 2000
- Cell death and cancer: replacement of apoptotic genes and inactivation of death suppressor genes in therapyGene Therapy, 1998
- The Novel Receptor TRAIL-R4 Induces NF-κB and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death DomainImmunity, 1997
- TRAIL-R2: a novel apoptosis-mediating receptor for TRAILThe EMBO Journal, 1997
- An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAILScience, 1997
- The Receptor for the Cytotoxic Ligand TRAILScience, 1997
- Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5Science, 1997
- The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of ApoptosisScience, 1997
- Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome cPublished by Elsevier ,1996
- Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell deathCell, 1993